Each year, the National Cancer Institute (NCI) prepares a report to communicate to the President and to Congress NCI’s research priorities, progress made to date, scientific areas of opportunity that will advance cancer research and improve patients’ lives, and the funding needed to do so.
This year, in addition to highlighting scientific opportunities, the FY2019 report included stories to highlight how investments in cancer research help people living longer and healthier lives. One of these stories is a profile of NF Hero Philip Moss, relaying his NF journey since April 2015, when he first joined the Phase II MEK inhibitor clinical trial.
Philip remains in the trial, and the tumor on his neck has shrunk by half. In this video from December 2016, Philip gave an update on the incredible progress.
Read more about Philip’s journey in the NCI Annual Plan here.
